Improved pathology reporting in NAFLD/NASH for clinical trials.
作者信息
Langford Caitlin Rose, Goldinger Marc H, Treanor Darren, McGenity Clare, Dillman Jonathan R, Allende Daniela S, Goldin Robert, Brunt Elizabeth M, Zatloukal Kurt, Denk Helmut, Fleming Kenneth A
机构信息
Perspectum Ltd, Oxford, UK
Perspectum Ltd, Oxford, UK.
出版信息
J Clin Pathol. 2022 Feb;75(2):73-75. doi: 10.1136/jclinpath-2021-207967. Epub 2021 Nov 9.
Abstract
摘要
相似文献
1
Improved pathology reporting in NAFLD/NASH for clinical trials.改善用于临床试验的非酒精性脂肪性肝病/非酒精性脂肪性肝炎的病理报告。
J Clin Pathol. 2022 Feb;75(2):73-75. doi: 10.1136/jclinpath-2021-207967. Epub 2021 Nov 9.
2
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.非酒精性脂肪性肝病——组织学评分系统：一项大型队列单中心评估研究。
APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742.
3
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.肠-胰-肝轴作为治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎的靶点。
Int J Mol Sci. 2020 Aug 13;21(16):5820. doi: 10.3390/ijms21165820.
4
Apoptosis and non-alcoholic fatty liver diseases.细胞凋亡与非酒精性脂肪性肝病。
World J Gastroenterol. 2018 Jul 7;24(25):2661-2672. doi: 10.3748/wjg.v24.i25.2661.
5
NAFLD: Reporting Histologic Findings in Clinical Practice.非酒精性脂肪性肝病：临床实践中的组织学发现报告
Hepatology. 2021 May;73(5):2028-2038. doi: 10.1002/hep.31599.
6
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的组织病理学
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
7
Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid.非酒精性脂肪性肝炎中的脂肪酸：聚焦于十五烷酸。
PLoS One. 2017 Dec 15;12(12):e0189965. doi: 10.1371/journal.pone.0189965. eCollection 2017.
8
Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.血清铁蛋白与非酒精性脂肪性肝病的关系：一项荟萃分析。
Lipids Health Dis. 2017 Dec 2;16(1):228. doi: 10.1186/s12944-017-0613-4.
9
The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.他汀类药物在非酒精性脂肪性肝病治疗中的作用。
Curr Pharm Des. 2018;24(38):4587-4592. doi: 10.2174/1381612825666190117114305.
10
Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH).非酒精性脂肪性肝炎 (NASH) 的分子机制和新治疗策略。
Int J Mol Sci. 2014 Apr 29;15(5):7352-79. doi: 10.3390/ijms15057352.
引用本文的文献
1
Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy.肝活检大小对通过二次谐波产生/双光子激发荧光显微镜评估代谢相关脂肪性肝病纤维化的影响。
JHEP Rep. 2025 May 8;7(8):101449. doi: 10.1016/j.jhepr.2025.101449. eCollection 2025 Aug.
2
Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis.靶向治疗策略作为肥胖诱导性脂肪性肝炎的替代和可持续治疗选择。
Rev Endocr Metab Disord. 2025 Jun 25. doi: 10.1007/s11154-025-09980-7.
3
Natural Language Processing to extract SNOMED-CT codes from pathological reports.自然语言处理从病理报告中提取 SNOMED-CT 编码。
Pathologica. 2023 Dec;115(6):318-324. doi: 10.32074/1591-951X-952.
本文引用的文献
1
NAFLD: Reporting Histologic Findings in Clinical Practice.非酒精性脂肪性肝病：临床实践中的组织学发现报告
Hepatology. 2021 May;73(5):2028-2038. doi: 10.1002/hep.31599.
2
Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist.临床试验中肝活检的可靠性：一位肝脏病理学家的思考
J Hepatol. 2020 Dec;73(6):1310-1312. doi: 10.1016/j.jhep.2020.08.014. Epub 2020 Sep 2.
3
Determining the reliability of liver biopsies in NASH clinical studies.确定肝活检在非酒精性脂肪性肝炎临床研究中的可靠性。
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):653-654. doi: 10.1038/s41575-020-00363-8.
4
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.肝活检评估的可靠性欠佳对随机临床试验有影响。
J Hepatol. 2020 Dec;73(6):1322-1332. doi: 10.1016/j.jhep.2020.06.025. Epub 2020 Jun 28.
5
Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology.英国胃肠病学会、皇家放射学院和皇家病理学院临床实践中肝活检使用指南。
Gut. 2020 Aug;69(8):1382-1403. doi: 10.1136/gutjnl-2020-321299. Epub 2020 May 28.
6
Managing the Silent Epidemic of Nonalcoholic Fatty Liver Disease.应对非酒精性脂肪性肝病这一无声的流行病。
Fed Pract. 2019 Jan;36(1):12-13.
7
Can the completeness of radiological cancer staging reports be improved using proforma reporting? A prospective multicentre non-blinded interventional study across 21 centres in the UK.可否通过使用表格报告来提高癌症分期报告的放射学完整性？一项在英国 21 个中心进行的前瞻性多中心非盲干预研究。
BMJ Open. 2018 Oct 2;8(10):e018499. doi: 10.1136/bmjopen-2017-018499.
8
Inter-radiologist agreement using Society of Abdominal Radiology-American Gastroenterological Association (SAR-AGA) consensus nomenclature for reporting CT and MR enterography in children and young adults with small bowel Crohn disease.采用美国胃肠病学会-腹部放射学会（SAR-AGA）共识术语报告儿童和青年小肠克罗恩病的 CT 和 MR 肠造影的放射科医生间协议。
Abdom Radiol (NY). 2019 Feb;44(2):391-397. doi: 10.1007/s00261-018-1743-5.
9
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.非酒精性脂肪性肝炎是肝移植候选者中肝细胞癌增长最快的病因。
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3. doi: 10.1016/j.cgh.2018.05.057. Epub 2018 Jun 14.
10
ESR paper on structured reporting in radiology.放射学中关于结构化报告的红细胞沉降率论文。
Insights Imaging. 2018 Feb;9(1):1-7. doi: 10.1007/s13244-017-0588-8. Epub 2018 Feb 19.
Zotero 插件